Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Sewanti Limaye; Prashant Kumar; Ramya Pragya; Janani Sambath; Darshana Patil; Ajay Srinivasan; Sachin Apurva; Navin Srivastava; Sanket Patil; Revati Patil; Vineet Datta; Dadasaheb Akolkar; Rajan Datar

doi:10.18632/oncotarget.28262

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

PDF | How to cite

Oncotarget. 2022; 13:982-982. https://doi.org/10.18632/oncotarget.28262

Metrics: PDF 724 views | ?

Sewanti Limaye¹, Prashant Kumar^2,3,4, Ramya Pragya¹, Janani Sambath^3,4, Darshana Patil², Ajay Srinivasan², Sachin Apurva², Navin Srivastava², Sanket Patil², Revati Patil², Vineet Datta², Dadasaheb Akolkar² and Rajan Datar²

¹Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
²Datar Cancer Genetics Limited, Nasik, Maharashtra, India
³Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India
⁴Manipal Academy of Higher Education, Manipal, Karnataka, India

Published: August 04, 2022

Copyright: © 2022 Limaye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The patient provided consent (by signing on a consent document) at the time of tumor tissue and blood sample collection stating willingness to:

Provide the required sample for tumor molecular profiling.
Research use of deidentified data including publication of (deidentified) findings.

Original article: Oncotarget. 2020; 11:4358–4363. DOI: https://doi.org/10.18632/oncotarget.27809

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28262

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer